三维后装近距离放疗三程加速部分乳房照射安全:TRIUMPH-T试验首次结果
TRIUMPH-T是一项前瞻性2期多中心临床试验,对保乳术后筛选的乳腺癌患者采用近距离放疗施源器给予22.5 Gy分3次、每次7.5 Gy的三程加速部分乳房照射。185例患者中位随访3.63年,慢性毒性低,94%美容效果极好或良好,无4级毒性,同侧局部复发2例(1.1%)。作者认为该超短程方案可行且毒性极低,可能成为符合条件的患者中标准5天10次加速部分乳房照射的替代方案。
要点
- 三程近距离放疗为22.5 Gy分3次、每次7.5 Gy,靶区为手术腔外1至2 cm。
- 185例中位随访3.63年,94%美容效果极好或良好,无4级毒性。
- 同侧局部复发2例(1.1%)、淋巴结复发2例(1.1%),无远处复发。
核心结论
- 超短程乳腺近距离放疗可行且毒性极低,在符合条件的患者中可能成为标准5天10次加速部分乳房照射的替代方案。
- 该前瞻性试验的患者将继续随访以评估长期结局。
研究设计与样本
- 前瞻性2期多中心临床试验,对保乳术后筛选的乳腺癌患者采用近距离放疗施源器给予22.5 Gy分3次、每次7.5 Gy。
- 计划治疗体积为手术腔外1至2 cm;入组标准为年龄≥45岁、单灶浸润性或原位肿瘤≤3 cm、切缘阴性、雌激素或孕激素受体阳性且无腋窝淋巴结转移。
- 要求满足严格剂量学参数,随访信息由参与中心收集;共200例前瞻性入组,其中185例可随访,中位随访3.63年。
主要发现
- 3次近距离放疗与低慢性毒性相关,94%患者美容效果极好或良好,无4级毒性。
- 治疗部位3级纤维化占1.7%,1级或2级纤维化占32%;另有1例肋骨骨折。
- 其他晚期毒性包括1级色素沉着7.4%、1级毛细血管扩张2%、有症状血清肿1.7%、腔隙脓肿1.7%、有症状脂肪坏死1.1%。
- 同侧局部复发2例(1.1%)、淋巴结复发2例(1.1%),无远处复发;另有对侧乳腺癌1例和第二原发恶性肿瘤(肺癌)2例。
临床怎么用
- 作者认为,超短程乳腺近距离放疗在符合条件的患者中可能成为标准5天10次加速部分乳房照射的替代方案。
局限性
- 该前瞻性试验的患者将继续随访以评估长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Shorter courses of breast radiotherapy are offered as an alternative to 4 weeks of whole-breast irradiation after lumpectomy, including brachytherapy. A prospective phase 2multi-institution clinical trial to study 3-fraction accelerated partial breast irradiation delivered by brachytherapy was conducted. METHODS AND MATERIALS: The trial treated selected breast cancers after breast-conserving surgery with brachytherapy applicators that delivered 22.5 Gy in 3 fractions of 7.5 Gy. The planning treatment volume was 1 to 2 cm beyond the surgical cavity. Eligible women were age ≥45 years with unicentric invasive or in situ tumors ≤3 cm excised with negative margins and with positive estrogen or progesterone receptors and no metastases to axillary nodes. Strict dosimetric parameters were required to be met and follow up information was collected from the participating sites. RESULTS: Two hundred patients were prospectively enrolled; however, a total of 185 patients who were enrolled were followed for a median of 3.63 years. Three-fraction brachytherapy was associated with low chronic toxicity. There was excellent or good cosmesis in 94% of patients. There were no grade 4 toxicities. Grade 3 fibrosis at the treatment site was present in 1.7% and 32% percent had grades 1 or 2 fibrosis at the treatment site. There was 1 rib fracture. Other late toxicities included 7.4% grade 1 hyperpigmentation, 2% grade 1 telangiectasias, 1.7% symptomatic seromas, 1.7% abscessed cavities, and 1.1% symptomatic fat necrosis. There were 2 (1.1%) ipsilateral local recurrences, 2 (1.1%) nodal recurrences and no distant recurrences. Other incidents included one contralateral breast cancer and 2 second malignancies (lung). CONCLUSIONS: Ultra-short breast brachytherapy is feasible and has excellent toxicity and could be an alternative to standard 5-day, 10 fraction accelerated partial breast irradiation in eligible patients. Patients from this prospective trial will continue to be followed to evaluate long-term outcomes.
引用
- Yashar C, Khan AJ, Chen P, et al. Three-Fraction Accelerated Partial Breast Irradiation (APBI) Delivered With Interstitial Brachytherapy Is Safe: First Results From the Tri-fraction Radiation Therapy Used to Minimize Patient Hospital Trips (TRIUMPH-T) Trial. Pract Radiat Oncol. 2023. PMID: 37140504. doi:10.1016/j.prro.2023.03.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。